Synchronous double primary lung cancers are uncommon in clinical practice and are frequently misdiagnosed as pulmonary metastases. Because treatment strategies and prognosis differ significantly between these two conditions, distinguishing synchronous primary lung cancers from intrapulmonary metastatic disease is of great clinical importance. Whole-body PET/CT (Positron Emission Tomography/Computed Tomography) using the radiotracer 18F-FDG provides superior capability in assessing the metabolic characteristics of pulmonary lesions, thereby aiding in the evaluation of their malignant potential. We present a case of synchronous double primary lung cancers diagnosed based on whole-body PET/CT findings, along with a review of similar cases previously reported in the literature.
18F-FDG PET/CT FINDINGS IN SYNCHRONOUS DOUBLE PRIMARY LUNG ADENOCARCINOMAS: A CASE REPORT
15
Views
0
Downloads
Keywords
Lung cancer; PET/CT; Multiple primary lung cancer; Synchronous MPLC; 18F-FDG; Pulmonary adenocarcinoma.
Abstract
References
[1]
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834
Google Scholar
[2]
Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606–12.
Google Scholar
[3]
Li J, Yin B, Liu Y, Huang H. Bilateral synchronous double primary lung cancer: A case report. Clinical Case Reports. 2024;12:e8635. https://doi.org/10.1002/ccr3.8635
Google Scholar
[4]
Chen C, Huang X, Peng M, Liu W, Yu F, Wang X. Multiple primary lung cancer: a rising challenge. J Thorac Dis. 2019;11:S523–36. https://doi.org/10.21037/jtd.2019.01.56
Google Scholar
[5]
Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. The Lancet Oncology. Elsevier; 2004;5:531–40. https://doi.org/10.1016/S1470-2045(04)01564-5
Google Scholar
[6]
Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of Positron Emission Tomography for Diagnosis of Pulmonary Nodules and Mass LesionsA Meta-analysis. JAMA. 2001;285:914–24. https://doi.org/10.1001/jama.285.7.914
Google Scholar
[7]
Vansteenkiste JF, Stroobants SG. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J. 2001;17:802–20. https://doi.org/10.1183/09031936.01.17408020
Google Scholar
[8]
Chou T-Y, Dacic S, Wistuba I, Beasley MB, Berezowska S, Chang Y-C, et al. Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2025;20:311–30. https://doi.org/10.1016/j.jtho.2024.11.016
Google Scholar
[9]
Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:906–14. https://doi.org/10.1007/s00259-013-2672-8
Google Scholar
[10]
Takada K, Toyokawa G, Tagawa T, Kohashi K, Akamine T, Takamori S, et al. Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer. Anticancer Res. 2017;37:7073–82. https://doi.org/10.21873/anticanres.12180
Google Scholar